|
Opportunities and Challenges from a Paradigm Shift between Pharmas and Biotechs Seminar Hosted by Tech Venture Business Network (TVBN)
Keelung Hong, Ph. D., Founder, Chairman & CEO of Taiwan Liposome Company A major paradigm shift is taking place between big Pharmas and Biotechs. In our July mixer, Dr. Hong will address some important issues facing biotech startups brought forth by this paradigm shift. Using Taiwan Liposome Company as an example, Dr. Hong will also discuss opportunities and challenges for Asian biotech companies conducting business across the Pacific. Please RSVP to rsvp@tech-vbn.org Admission: free for TVBN and CBA members who RSVP by 6PM on July 25, 2006. $5 for non-members or members whose reply is received past the deadline. Dr. Hong is a pioneer in explicating the structure and function of biomembranes and the effects of long-term exposure to general anesthetics. His longstanding interest in improving cancer therapy has led to a series of breakthroughs in drug carrier technology for improving drug and gene delivery. This line of research has resulted in a number of patents and been recognized with 2005 Pioneering Technology Innovation Award from Taiwan Ministry of Economic Affairs. After being a consultant to several biotech companies, Dr. Hong founded Taiwan Liposome Company in Taiwan and co-founded Hermes Biosciences in the United States. He currently serves as Chairman & CEO of Taiwan Liposome Company and its US subsidiary, TLC Biopharmaceuticals. Dr. Hong was educated at Taiwan Cheng Kung University, the University of Texas at El Paso, and the University of California at Berkeley where he earned a Ph.D. degree in Chemistry. Afterwards, he conducted postdoctoral research at Stanford University and was a research scientist at the University of California, San Francisco for twenty years. Dr. Hong has authored or coauthored more than a hundred scientific publications. In 2005 he delivered the inaugural James W. Whalen Memorial Chemistry Lecture at University of Texas, El Paso.
|
||